Andrew Lawrence Taylor, Chief Financial Officer of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO), filed a Form 4 on August 28, 2026, disclosing a share withholding transaction dated August 26, 2026, in connection with the vesting of restricted stock units.

Key Highlights

  • Reporting person: Andrew Lawrence Taylor, Chief Financial Officer of Orchestra BioMed Holdings, Inc.
  • Transaction date: August 26, 2026, involving Common Stock, par value $0.0001 per share.
  • Shares withheld: 3,076 shares disposed of (transaction code F) at a price of $5.26 per share.
  • Purpose: The filing states shares were withheld by the issuer to satisfy tax withholding obligations in connection with RSU vesting; no shares were sold in the market.
  • Beneficial ownership following transaction: 589,989 shares of common stock held directly.

RSU Vesting and Tax Withholding Details for Orchestra BioMed CFO

According to the Form 4 filed with the U.S. Securities and Exchange Commission, Taylor Andrew Lawrence, serving as Chief Financial Officer of Orchestra BioMed Holdings, Inc., reported a single non-derivative securities transaction on August 26, 2026. The transaction involved the disposition of 3,076 shares of Orchestra BioMed Common Stock, par value $0.0001 per share, at a price of $5.26 per share, under transaction code F.

The filing's explanation of responses states that the transaction "represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units ('RSUs')." The filing further notes that "no shares were sold in the market as a result of the vesting of these RSUs and the satisfaction of tax withholding obligations." Following this transaction, the reporting person directly holds 589,989 shares of common stock, according to the filing.

No derivative securities transactions were reported in Table II of the filing. The Form 4 was filed by one reporting person and is not an amendment to a prior filing. The form was signed by Andrew Taylor and dated August 28, 2026.

What Was Disclosed

The filing discloses that Orchestra BioMed's CFO had 3,076 shares of common stock withheld at $5.26 per share on August 26, 2026, to cover tax obligations tied to RSU vesting, leaving a direct beneficial ownership of 589,989 shares.